<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02238470</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-ACO-2010-10</org_study_id>
    <secondary_id>PI11/00296</secondary_id>
    <nct_id>NCT02238470</nct_id>
  </id_info>
  <brief_title>Intracerebral Hemorrhage Due to Oral Anticoagulants: Prediction of the Risk by Magnetic Resonance</brief_title>
  <acronym>HERO</acronym>
  <official_title>Intracerebral Hemorrhage Due to Oral Anticoagulants in the Secondary Prevention of Ischemic Stroke: Prediction of the Risk by the Detection of Leukoaraiosis and Microbleeding With Magnetic Resonance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Magnetic Resonance Imaging may predict the
      risk of Intracerebral Hemorrhage for patients with ischemic stroke who receive indefinite
      oral anticoagulation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES. To evaluate whether Magnetic Resonance (MR) helps in predicting the risk of
      Intracranial Hemorrhage (ICH-OA) in patients with ischemic stroke who will receive Oral
      Anticoagulants (OA) for the secondary prevention of stroke. By allowing the detection and
      quantification of leukoaraiosis and microbleeding, MR aids in the assessment of hypertensive
      and/or amyloid angiopathy, two findings that may increase the risk of ICH-OA. The study of
      these and other known variables associated with the risk of ICH-OA will improve the selection
      of patients to be treated with OA. METHODOLOGY. A prospective, observational, multicentric
      study of 1000 patients with stroke, older than 65 y, candidates to receive OA indefinitely.
      The primary end-point is ICH-OA. A MR will be performed before starting the treatment, in
      which we will evaluate the presence and degree of leukoaraiosis (Fazekas's scale) and
      microbleeding (BOMBS scale). A visit will be scheduled at the first month after inclusion,
      and thereafter the patient will be followed-up during 2 years with phone interviews, to
      evaluate the appearance of the primary end-point. We will register data about demographics,
      vascular risk factors, anticoagulation, MR, echocardiography and co-morbidity. With those
      variables associated with ICH-OA in the univariate analyses, a regression analysis will be
      performed, in which ICH-OA will be the dependent variable. Finally, each independent
      predictive variable will receive a score to elaborate a predictive model of ICH-OA.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Intracranial Hemorrhage</measure>
    <time_frame>every 3 months after stroke, until 24 months</time_frame>
    <description>Telephone interview every 3 months, starting 3 months after ischemic stroke (3, 6, 9, 12, 15, 18, 21 and 24 months)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke</measure>
    <time_frame>within 24 months after inclusion</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Oral anticoagulants</arm_group_label>
    <description>Patients who will receive oral anticoagulants indefinitely for the secondary prevention of cardioembolic stroke</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral anticoagulants</intervention_name>
    <description>Comparison of patients receiving oral anticoagulants with or without microbleeds in magnetic resonance imaging</description>
    <arm_group_label>Oral anticoagulants</arm_group_label>
    <other_name>warfarin</other_name>
    <other_name>coumarin</other_name>
    <other_name>dabigatran</other_name>
    <other_name>rivaroxaban</other_name>
    <other_name>apixaban</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to tertiaty hospital for cardioembolic ischemic stroke
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 65 y

          2. TIA or ischemic stroke

          3. The patient will receive indefinitely treatment with oral anticoagulants for the
             secondary prevention of cardioembolic stroke

          4. No previous treatment with oral anticoagulants

          5. Signed consent before performing a Magnetic Resonance

          6. Long-term follow-up will be possible

        Exclusion Criteria:

          1. The patient will receive oral anticoagulation as a primary prevention treatment

          2. The etiology that motivates the onset of oral anticoagulants is not cardioembolism

          3. Absolute contraindication to receive oral anticoagulants

          4. Arterial hypertension that is not controlled, hypertensive crisis

          5. Dementia

          6. Live-expectancy less than 1 year

          7. Any social or psychological reason that prevents follow-up

          8. Contraindication to perform a Magnetic Resonance examination

          9. Patients who received oral antiacoagulants prior to the current stroke

         10. The Magnetic Resonance imaging was performed more than 1 month after the onset of
             treatment with oral anticoagulants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan Martí-Fàbregas, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biomedical Research Institute Sant Pau (IIB Sant Pau)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova IRCCS</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundació Hospital Asil Granollers</name>
      <address>
        <city>Granollers</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Mataró</name>
      <address>
        <city>Mataró</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Moisés Broggi</name>
      <address>
        <city>Sant Joan Despí</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mutua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Cinta</name>
      <address>
        <city>Tortosa</city>
        <state>Tarragona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Albacete</name>
      <address>
        <city>Albacete</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Basurto</name>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital CA de Burgos</name>
      <address>
        <city>Burgos</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcántara</name>
      <address>
        <city>Cáceres</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Donostia</name>
      <address>
        <city>Donostia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de León</name>
      <address>
        <city>León</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Rioja</name>
      <address>
        <city>Logroño</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Médico Asturias</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital CU de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2014</study_first_submitted>
  <study_first_submitted_qc>September 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2014</study_first_posted>
  <last_update_submitted>September 21, 2015</last_update_submitted>
  <last_update_submitted_qc>September 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ischemic stroke</keyword>
  <keyword>Intracerebral hemorrhage</keyword>
  <keyword>Subdural hemorrhage</keyword>
  <keyword>Microbleed</keyword>
  <keyword>Leukoaraiosis</keyword>
  <keyword>Oral anticoagulants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Leukoaraiosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

